SCHEMBL12038352

SCHEMBL12038352

CC(=O)Oc1c(F)c(F)c2cc(C(=O)ON3C(=O)CCC3=O)c(=O)oc2c1F

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ GBA1 P04062 1/20 0.33
▸ ADORA3 P0DMS8 3/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ PREP P48147 1/20 0.32
▸ CELA1 Q9UNI1 1/20 0.32
▸ GLA P06280 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ CASP1 P29466 1/20 0.30
▸ CASP7 P55210 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12038354 0.87 MAPT (0.33) MAPT
SCHEMBL12038371 0.87 LMNA (0.32) LMNAHTTGBA1GLAKDM4E
SCHEMBL12038326 0.86 MEN1 (0.33) ADORA3ADORA2AADORA1MEN1ALDH1A1
SCHEMBL12038356 0.82 LMNA (0.33) LMNAHTTGBA1ADORA3ADORA2A
SCHEMBL12038347 0.78 GLA (0.38) LMNAHTTGLAKDM4EMEN1
SCHEMBL12038365 0.77 MEN1 (0.31) ADORA3ADORA2AADORA1MEN1MAPT
SCHEMBL12038332 0.76 MAOB (0.34) GLAKDM4EMEN1ALDH1A1GAA
SCHEMBL12038321 0.75 GAPDH (0.39) LMNAGLAKDM4EMEN1ALDH1A1
SCHEMBL12038299 0.75 MEN1 (0.39) KDM4EMEN1ALDH1A1MAPTCASP1
SCHEMBL12038292 0.74 MAOB (0.37) LMNAKDM4EMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES CYP3A7, XPO7, HCCS LMNA 332/4885HTT 2461/4885GBA1 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback